Peter Lurie, a former FDA official who now directs the Center for Science in the Public Interest, described allowing peptides to market without clinical testing as a "profound threat" to the FDA's decades-long drug vetting system
cloudy, discolored, or particulate solutions should not be used
Lacosamide as the first add-on therapy in adult patients with focal epilepsy: a multicenter real-world study
Combined Ozempic and Wegovy sales crossed $26 billion in 2024, growing at around 40 percent a year
It asks validated PHQ-2 depression items, a dedicated family-history MEN-2 and medullary thyroid cancer screen, pregnancy and breastfeeding status, suicidal thoughts, medication allergies, blood pressure stages, and resting heart rate ranges before it ever asks for the patients name